Clarity Pharmaceuticals’ SAR-bisPSMA patent granted in the U.S.
Sydney, Australia 6 May 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the U.S. Patent and Trademark Office (USPTO) has granted the patent application for Clarity’s SAR-bisPSMA compound and its variants. The grant of the patent application bolsters Clarity’s strong Intellectual Property…